retatrutide ly3437943 phase 2 trial obesity nejm 2023 is gaining attention in metabolic research for its triple agonist activity on GIP, GLP-1, and glucagon receptors. In this carousel, we summarize recent clinical study findings related to weight management, type A Placebo-Controlled Trial of Subcutaneous
Description
That includes four prefilled pens, which amounts to a 28-day supply
2023) also reduce body weight ~ 10-15%
Do not blast it directly onto the powder
N Engl J Med 2016;375:31122.ArticlePubMedPMC 46
The most prescribed GLP-1RA was semaglutide 1 mg (33%), followed by tirzepatide 7.5 mg (25%)
Ethics declarations Competing interests J.R., S.W., J.N., P.T., C.P., L.L., Y.H., A.I.R., J.A.S
